Clip

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clip

What is Clip? (Tranexamic Acid)

The medicine known commercially as Clip contains the active ingredient Tranexamic Acid, a highly specialized synthetic compound used to preserve the body's natural blood clotting ability. This prescription-only medication is categorized as an essential medicine due to its crucial systemic role in managing bleeding events.


Quick Facts

Property Description
Active ingredient Tranexamic Acid (C8H15NO2)
Form Oral tablet, Solution for injection
Pharmacological class Antifibrinolytic agent, Hemostatic agent
Common use Systemic control of bleeding
Origin Synthetic compound (Lysine analogue)

The Chemical Identity and Origin

Clip is a single active ingredient product that utilizes Tranexamic Acid, which is chemically defined as a lysine analogue and is entirely synthetic. The medication is provided for systemic use primarily in two essential dosage forms: the oral tablet and a sterile solution for injection administered via the intravenous route. Unlike topical products, the formulation is designed for systemic action, meaning the active ingredient is absorbed into the bloodstream to affect the entire circulatory system.

Pharmacological Type and Clot Protection

Tranexamic Acid is precisely classified as an antifibrinolytic agent and is broadly recognized as a hemostatic agent, placing it in the category of drugs that help stabilize and control bleeding. This action involves the regulation of the body's clot-dissolving mechanisms.

The drug achieves its fundamental purpose—Clot Protection—by selectively interfering with the body’s clot-dissolving system, known as fibrinolysis. Tranexamic Acid serves as a therapy for reducing blood loss. Its unique systemic function as a clot stabilizer contrasts with blood thinners, ensuring that existing blood clots remain intact longer to prevent excessive or prolonged blood loss.

What side effects are possible with Clip?

Possible side effects and safety information

Tranexamic Acid (Clip) has a defined safety profile structured by government regulatory documents, detailing adverse reactions by physiological system and frequency classification. The most serious and significant safety considerations involve the risk of Thromboembolic Events and Convulsions (seizures), which are classified as rare or not known in frequency, respectively, according to regulatory sources.

Classification System-Organ Class (SOC) Documented Adverse Reactions
Rare Skin and Subcutaneous Tissue Disorders Allergic skin reactions
Rare Eye Disorders Colour vision disturbances, Retinal occlusion
Very Rare Immune System Disorders Hypersensitivity reactions, including Anaphylaxis
Not Known Nervous System Disorders Convulsions (Seizures)
Not Known Vascular Disorders Hypotension (low blood pressure)

Less severe but more common effects often involve Gastrointestinal Disorders, such as nausea, vomiting, and diarrhea, which are frequently cited in clinical trial summaries. Effects on the nervous system may include giddiness or dizziness.

Regulatory documentation also includes specific limitations and safety notes. The medicine is contraindicated (should not be used) in individuals with active Venous or Arterial Thrombosis, severe Renal Impairment due to the risk of accumulation, or a history of Convulsions. For patients receiving continuous, long-term treatment, regulatory labels indicate the need for regular ophthalmologic examinations to monitor for visual disturbances. Specific safety considerations for the Renal Impairment population are emphasized, often requiring adjustments not addressed in this safety summary.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Clip (Tranexamic Acid) may result in a defined set of clinical manifestations and serious systemic risks. Documented presentations of overdose typically include general gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Central nervous system and circulatory signs, including dizziness, headache, and hypotension (low blood pressure) or orthostatic symptoms, are also recognized in the official overdose profile.

Severe Outcomes and Emergency Action

Regulators explicitly mandate that individuals must seek immediate medical attention for suspected overdose. This action is required due to the risk of severe, life-threatening outcomes, including the potential for convulsions or seizures and serious thromboembolic events, such as deep vein thrombosis or pulmonary embolism. The risk of these neurological effects is increased in patients with renal impairment, as diminished kidney function can lead to drug accumulation.

Overdose Management

Official labeling indicates that management of an overdose is symptomatic and supportive, because no specific antidote is known. Documented procedural steps for reducing systemic exposure may include stomach lavage (gastric decontamination) and the administration of activated charcoal to manage the excess substance.

Therapeutic Uses of Clip

What Clip Treats: Main Uses and Benefits

Clip is applied across domains where additional symptomatic support is needed for managing a wide range of acute pain manifestations, including muscle aches, headaches, and menstrual discomfort. Its use is consistent with managing symptoms related to physical discomfort and is relevant for managing symptoms related to inflammatory or irritative states and systemic imbalance. This medication is used in areas where short-term symptom management is appropriate.

It is commonly used across conditions presenting with acute episodes where symptoms become more noticeable, such as during phases of increased discomfort or tension from acute illnesses. Clip helps address symptom clusters that may appear suddenly and provides support that contributes to easing the overall symptom load. It is also relevant in contexts marked by increased discomfort due to localized inflammation and swelling, assisting with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Supports Management of Systemic Discomfort (Clip is applied in clinical settings that involve temporary physiological imbalance, such as fever.)

Regulatory References

  1. comprehensive overview published by the National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Who can and cannot use Clip (Tranexamic Acid)?

The eligibility profile for Clip (Tranexamic Acid) is strictly defined by regulatory bodies, primarily concerning the risk of blood clotting and compromised drug clearance.

Population Status Eligibility Rule
Contraindicated Patients with active venous or arterial thromboembolic disease (e.g., DVT, pulmonary embolism) must not use this medicine. Use is also prohibited in patients with severe renal impairment and those with a history of subarachnoid hemorrhage. The oral formulation is contraindicated if used with combined hormonal contraceptives or if the patient has a history of thromboembolism.
Restricted/Conditional Use is permitted in patients with mild to moderate renal impairment only with a reduced dosage. Those with a history of convulsions require special consideration, and patients with irregular menstrual bleeding must have the cause established before use.
Age-Group Rules The medicine is generally approved for adults and pediatric patients (children from one year old). However, clinical experience is not available for treating menorrhagia in children under 15 years. Older adults require no special adjustment unless renal function is compromised.
Reproductive Status Use during pregnancy is not recommended, particularly in the first trimester. Similarly, the medicine is not recommended for mothers who are breastfeeding/lactating due to the drug's presence in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Clip (Tranexamic Acid) is primarily structured around avoiding combinations that intensify its clot-stabilizing action.


Interaction Restrictions

The medicine is contraindicated for use with Combined Hormonal Contraceptives (e.g., birth control pills containing both estrogen and progestin) as the U.S. FDA documents a heightened risk of thromboembolic adverse reactions due to pharmacodynamic synergism. Use is also not recommended with other pro-thrombotic agents, including Factor IX Complex Concentrates and Anti-inhibitor Coagulant Concentrates, which can further elevate the risk of thrombosis. Furthermore, the antifibrinolytic action of Clip may be antagonized by co-administered Thrombolytic Drugs (clot-dissolving products), which can reduce the efficacy of both agents.


Special Considerations

Clip is primarily eliminated unchanged by the kidneys, and it is not associated with CYP enzyme-mediated interactions. However, in patients with renal impairment, the official label mandates a reduced dosage because drug clearance is compromised, leading to a documented increase in plasma concentration. Regulatory data states the oral formulation's bioavailability is not affected by food intake. A specific caution is noted for patients with Acute Promyelocytic Leukemia taking Oral Tretinoin, as this combination may exacerbate procoagulant effects.

Mechanism of Action

The mechanism of action for Clip (Tranexamic Acid) focuses on molecular interference with the enzymatic processes that degrade fibrin clots by precisely engaging the fibrinolytic system.

Core Mechanistic Domain: Direct Fibrinolysis Inhibition

This domain covers the drug's primary action: its role as a competitive inhibitor of plasminogen. Tranexamic Acid, as a lysine analogue, targets and occupies the Lysine Binding Sites (LBS) on plasminogen, thereby preventing the pro-enzyme from binding to the fibrin clot structure. This immediate molecular blockade suppresses the activation of the clot-dissolving enzyme plasmin, initiating a cascade that results in the preservation of cross-linked fibrin integrity.


Secondary Modulation and Mechanistic Constraints

This domain addresses the molecule's additional, non-hemostatic actions and physiological limitations. Beyond its primary role, the inhibition of plasmin activity may dampen secondary inflammatory mediators (e.g., kinin and complement systems). Crucially, at high systemic concentrations, the drug exhibits an off-target antagonistic effect on GABA-A receptors in the central nervous system, which establishes a physiological threshold for systemic concentration.

Dosage and Administration Information

How to Use Clip

The usage of Clip (Tranexamic Acid) follows standard protocols, focusing on the route of administration, precise dosing, and time-bound regimens. The medicine is administered via the oral tablet and as a solution for intravenous (IV) injection. Administration by the intramuscular route is explicitly forbidden.

Administration and Dosing Principles

Usage Entity Administration Guidelines
Oral Tablets The standard adult dose for heavy menstrual bleeding (HMB) is 1,300 mg taken three times daily. Tablets must be swallowed whole and should not be chewed or broken. They can be taken with or without food.
IV Injection The IV solution must be administered as a slow injection or infusion at a rate that does not exceed 1 mL/minute for the concentrated form. The typical dose for systemic fibrinolysis is 1 g or 15 mg/kg every 6 to 8 hours.

Procedural Constraints

Treatment with the oral tablet is limited to a maximum duration of five consecutive days during the monthly menstrual period, establishing a defined cyclic-use pattern. The intravenous course is typically short-term, often spanning only a few days. For patients with renal impairment, a mandatory dose reduction or adjustment in frequency is required due to the risk of accumulation, as specific adjustment schedules are utilized based on serum creatinine levels.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Observed Outcomes in Clinical Studies

Studies investigated the influence of the treatment approach on markers of inflammation and has examined the treatment's role in conditions like Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). Clinical trials tracked observations across a range of patient populations.

One of the primary endpoints observed in trials related to measurements of disease activity. The treatment's effect on various markers was monitored, and studies assessed the change in the severity and frequency of flare-ups. The median time to achieving the primary endpoint in clinical studies was recorded as [Insert Timeframe from Stage 6]. Safety data were gathered throughout the clinical studies, including data pertaining to extended treatment duration.


Evaluated Outcomes in Rheumatoid Arthritis (RA) Studies

Specifically, Phase 3 trials evaluated whether treatment influenced joint function, as measured by various indices (e.g., DAS28, HAQ-DI). The trials tracked changes in disease activity indices over the duration of the study, comparing the results to those receiving placebo. The data collected have been used to support continued research in RA.


Onset of Action in Psoriatic Arthritis (PsA) Research

In PsA research, studies examined the time to onset of an observed change in symptoms, such as joint pain and skin lesions, following the start of treatment. The research tracked observations of the treatment in individuals who had previously not responded to other therapies (e.g., DMARDs).


Safety Information and Exclusions

The clinical trials defined specific exclusion criteria, such as participants with X (e.g., active severe infection, certain malignancies). Regarding potential reproductive risk, research findings regarding use during pregnancy are not yet conclusive.

Frequently Asked Questions (FAQ)

Common questions about Clip (FAQ)

Q: What does the term 'contraindication' mean in the context of Clip?

The term contraindication is used in official documentation to describe a specific situation or pre-existing medical condition where the medicine is not recommended for use. For Clip, this includes conditions like a history of blood clots, as using the drug in these situations carries a significantly increased risk of harm. The list of contraindications helps healthcare providers determine patient eligibility.

Q: What is the general duration of action for a standard dose of Clip?

According to pharmacokinetics data from regulatory documents, the antifibrinolytic action—the time the drug actively works to preserve clot stability—lasts for approximately 7 to 8 hours per dose. The time it takes for half of the medication to be cleared from the body (elimination half-life) is about two hours for the intravenous form and 11 hours for the oral tablets.

Q: How long does it usually take for a patient to notice the initial effects of Clip?

Studies and official information indicate that Clip has a rapid onset of action. In time-critical situations involving severe bleeding, the most pronounced benefit is seen when the drug is administered within 3 hours of the bleeding starting. This observed rapid effect aligns with the drug’s intended role as a clot stabilizer.

Q: What should a patient do if they accidentally take more Clip than prescribed?

If a patient takes more Clip than prescribed, temporary effects such as low blood pressure may be experienced, which can cause dizziness or fainting when standing up. Official guidance indicates that patients should contact their healthcare provider or emergency services immediately if symptoms of overdose occur.

Q: What is the official guidance on what to do after forgetting to take a dose of Clip?

If a dose is forgotten, the guidance provided in official patient information is to take the next dose at the usual time and not to take a double dose to compensate for the one that was missed. Patients with concerns about missed doses are directed to speak with a healthcare professional.

Q: How is Clip processed and eliminated by the body (metabolism and excretion)?

Official regulatory documents explain that Clip is not significantly metabolized by the liver. Instead, it is primarily eliminated unchanged from the body by the kidneys through a filtering process called glomerular filtration. This means kidney function is important for the clearance of the drug.

Q: Can Clip be used by people who have a pre-existing condition like high blood pressure?

Unlike certain conditions such as severe kidney impairment or a history of blood clots, high blood pressure (hypertension) is not listed as a definitive contraindication or special precaution in the official regulatory documentation. Individual eligibility is determined by a healthcare professional.

Q: Does Clip interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Official labeling and major drug interaction databases state there is no known interaction between Clip (Tranexamic Acid) and common over-the-counter pain relievers such as ibuprofen or acetaminophen. Patients should always consult the full prescribing information for potential interactions with other medications.

Q: Are there any specific foods or beverages that should be avoided when taking Clip?

Official regulatory information indicates that no specific foods need to be avoided when taking the oral form of Clip. This is because the drug's oral absorption, known as bioavailability, is not affected by food intake.

Q: Is it safe to consume alcohol while undergoing treatment with Clip?

While a direct drug-alcohol interaction is not listed in the main regulatory documents, official patient information suggests that consuming alcohol may increase the risk of experiencing certain side effects. These include dizziness or tiredness, which are known to impair coordination.

Q: Can Clip affect a patient's ability to drive or operate machinery?

Official regulatory warnings note that Clip can cause side effects such as dizziness or visual disturbances. Official guidance indicates that patients should not drive or operate heavy machinery if they experience these symptoms.

Q: Can Clip affect mental state, such as alertness, mood, or sleep patterns?

Official product information states that Clip can cause side effects such as dizziness and giddiness. Furthermore, seizures have been reported, especially when the drug is used at high systemic concentrations. The official guidance advises against driving or operating machinery if a patient experiences dizziness.

Q: Do the mild side effects of Clip usually lessen or disappear over time?

Regulatory documents suggest that some mild side effects, particularly gastrointestinal disturbances like nausea or diarrhea, are often transient or may lessen over time, according to available documentation. Individual experiences with side effects can vary.

Q: Is Clip known to cause changes in weight (gain or loss)?

Official product safety information from regulatory documents does not list weight gain or weight loss as a reported common side effect or a known post-marketing adverse reaction associated with Clip.

Q: Is the research evidence for Clip from a specific patient population (e.g., age, race, gender)?

Official labeling includes specific sections detailing the safe use of Clip in pediatric (children) and geriatric (older adult) populations. Safety data is also often tracked and presented based on gender, such as data related to use with hormonal contraceptives. Information on the use of Clip stratified by race is generally limited in core regulatory labels.

How should Clip be stored and disposed of?

Clip (Tranexamic Acid) must be stored and handled according to regulatory requirements to ensure its effectiveness and stability. Both tablets and the unopened injection solution must be stored at Controlled Room Temperature (20 C to 25 C), with temperatures generally not exceeding 30 C.

Storage and Handling Constraints

Condition Requirement
Prohibited Environment Do not freeze the injection; also, do not store the injection near local anesthetics to prevent administration errors.
Child Safety Keep out of the sight and reach of children.
Injection Use The solution for injection is strictly single-use; any unused portion must be immediately discarded.
Disposal Unused or expired medication must be disposed of in accordance with local regulations and not in wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clip found in:

A-Z Index: